Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-cash Items (2016 - 2022)

Historic Non-cash Items for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Q1 2022 value amounting to $83.3 million.

  • Arrowhead Pharmaceuticals' Non-cash Items rose 333085.64% to $83.3 million in Q1 2022 from the same period last year, while for Mar 2022 it was $83.3 million, marking a year-over-year increase of 333085.64%. This contributed to the annual value of $2.5 million for FY2021, which is 1417.74% down from last year.
  • Arrowhead Pharmaceuticals' Non-cash Items amounted to $83.3 million in Q1 2022, which was up 333085.64% from $149.3 million recorded in Q4 2021.
  • In the past 5 years, Arrowhead Pharmaceuticals' Non-cash Items ranged from a high of $149.3 million in Q4 2021 and a low of $2.4 million during Q2 2021
  • Its 5-year average for Non-cash Items is $36.9 million, with a median of $3.7 million in 2018.
  • Within the past 5 years, the most significant YoY rise in Arrowhead Pharmaceuticals' Non-cash Items was 574152.44% (2021), while the steepest drop was 9819.09% (2021).
  • Over the past 5 years, Arrowhead Pharmaceuticals' Non-cash Items (Quarter) stood at $3.7 million in 2018, then fell by 13.58% to $3.2 million in 2019, then dropped by 19.77% to $2.6 million in 2020, then surged by 5741.52% to $149.3 million in 2021, then plummeted by 44.24% to $83.3 million in 2022.
  • Its Non-cash Items was $83.3 million in Q1 2022, compared to $149.3 million in Q4 2021 and $2.5 million in Q3 2021.